《新股表現》鷹瞳科技-B(02251.HK)暗盤輕微高開後「潛水」 現低上市價逾7%
根據輝立交易平台顯示,明天掛牌的北京鷹瞳科技-B(02251.HK)暗盤輕微高開0.1%報75.2元欠承接,掉頭低見68.8元,現報69.3元,較上市價75.1元,低7.7%,成交13.9萬股。
鷹瞳是內地首批提供人工智能視網膜影像識別無創、快速、有效且可擴展早期檢測、診斷及健康風險評估解決方案的公司之一。公司自主開發的核心產品Airdoc-AIFUNDUS是一款人工智能醫療器械軟件,獲批用於輔助診斷糖尿病視網膜病變,以協助醫生做醫療診斷,為同類產品中首個獲得中國藥監局第三類醫療器械證書的醫療器械。是次來港上市共發售2,226.72萬股H股,並已引入包括CloudAlpha、廣發基金、LAV及WT等八家基石投資者,合共認購719.87萬股H股。10%公開發售獲逾5倍超購,認購一手中籤率15.55%;股份以招股範圍(75.1-81.3元)下限定價,料集資淨額約15.66億元,主要用於公司的核心產品Airdoc-AIFUNDUS持續優化、開發與商業化,用於資助硬件設備研發和生產,以及健康風險評估解決方案的研發等。上市聯席保薦人為瑞銀及中信証券。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.